University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Melbourne Medical School Collected Works
  • Melbourne Medical School Collected Works - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Melbourne Medical School Collected Works
  • Melbourne Medical School Collected Works - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future?

    Thumbnail
    Download
    published version (3.518Mb)

    Citations
    Scopus
    Web of Science
    Altmetric
    24
    20
    Author
    Ascierto, PA; McArthur, GA
    Date
    2017-08-08
    Source Title
    Journal of Translational Medicine
    Publisher
    BMC
    University of Melbourne Author/s
    McArthur, Grant
    Affiliation
    Melbourne Medical School
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Ascierto, P. A. & McArthur, G. A. (2017). Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future?. JOURNAL OF TRANSLATIONAL MEDICINE, 15 (1), https://doi.org/10.1186/s12967-017-1278-5.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/256879
    DOI
    10.1186/s12967-017-1278-5
    Abstract
    Anti-programmed death (PD)-1 and PD-ligand (L)-1 checkpoint inhibitors have revolutionized the therapy of several cancers. Immunotherapy of cancer can offer long-term durable benefit to patients, is active regardless of tumour histology, has a unique immune-related safety profile, and can be used in combination with other cancer treatments. In addition, recent research has shown that immune-based therapy can be used as adjuvant therapy, that outcomes may be influenced by dose, and that clinical activity is observed in patients with brain metastases. Despite our increased understanding of these agents, there are still several important questions that need to be answered. These include strategies to overcome primary and acquired resistance, the influence of mutational status on treatment outcomes, the optimal duration of treatment, and the need to identify novel combination regimens that offer increased anti-tumour potency and/or reduced toxicity. Here we review recent developments in these areas, with particular focus on new data reported at the 2017 ASCO Annual Meeting.

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [53039]
    • Melbourne Medical School Collected Works - Research Publications [502]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors